- Home
- CLIK vs INAB Comparison
CLIK vs INAB Comparison
Compare CLIK & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLIK
- INAB
- Stock Information
- Founded
- CLIK 2017
- INAB 2016
- Country
- CLIK Hong Kong
- INAB United States
- Employees
- CLIK N/A
- INAB N/A
- Industry
- CLIK
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- CLIK
- INAB Health Care
- Exchange
- CLIK NYSE
- INAB Nasdaq
- Market Cap
- CLIK 24.6M
- INAB 24.0M
- IPO Year
- CLIK 2024
- INAB 2021
- Fundamental
- Price
- CLIK $1.24
- INAB $0.24
- Analyst Decision
- CLIK
- INAB Strong Buy
- Analyst Count
- CLIK 0
- INAB 3
- Target Price
- CLIK N/A
- INAB $7.75
- AVG Volume (30 Days)
- CLIK 106.4K
- INAB 750.7K
- Earning Date
- CLIK 02-14-2025
- INAB 11-12-2024
- Dividend Yield
- CLIK N/A
- INAB N/A
- EPS Growth
- CLIK N/A
- INAB N/A
- EPS
- CLIK 0.06
- INAB N/A
- Revenue
- CLIK $5,657,132.00
- INAB N/A
- Revenue This Year
- CLIK N/A
- INAB N/A
- Revenue Next Year
- CLIK N/A
- INAB N/A
- P/E Ratio
- CLIK $20.89
- INAB N/A
- Revenue Growth
- CLIK 36.12
- INAB N/A
- 52 Week Low
- CLIK $1.15
- INAB $0.22
- 52 Week High
- CLIK $4.39
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- CLIK N/A
- INAB 38.43
- Support Level
- CLIK N/A
- INAB $0.23
- Resistance Level
- CLIK N/A
- INAB $0.32
- Average True Range (ATR)
- CLIK 0.00
- INAB 0.03
- MACD
- CLIK 0.00
- INAB -0.01
- Stochastic Oscillator
- CLIK 0.00
- INAB 10.62
About CLIK CLICK HOLDINGS LIMITED
Click Holdings Ltd is a human resources solutions provider, specializing in offering comprehensive human resources solutions. It is focused on talent sourcing and the provision of temporary and permanent personnel to customers and also in placing professional accountants and company secretaries, registered nurses and healthcare workers as well as other blue-collar workers, for direct hire and contract staffing roles. The Company operates in three segments, 1) professional solution services, 2) nursing solution services and 3) logistic and other solution services. Maximum revenue is generated from Professional solution services and Hong Kong.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.